Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 16/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332126 | 1.00 | SLC10A1 (0.45) | SLC10A1TSHRMAPTNPC1POLB | |
| SCHEMBL19332070 | 0.93 | SLC10A1 (0.41) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL19332195 | 0.91 | SLC10A1 (0.51) | SLC10A1 | |
| SCHEMBL30033987 | 0.90 | SLC10A1 (0.47) | SLC10A1TSHRMAPTNPC1POLB | |
| SCHEMBL19332176 | 0.90 | SLC10A1 (0.47) | SLC10A1TSHRMAPTNPC1POLB | |
| SCHEMBL19332096 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHR | |
| SCHEMBL22511215 | 0.89 | LMNA (0.41) | SLC10A1MAPTLMNA | |
| SCHEMBL29453420 | 0.89 | LMNA (0.41) | SLC10A1MAPTLMNA | |
| SCHEMBL21889666 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHRMAPTNPC1POLB | |
| SCHEMBL21889644 | 0.88 | SLC10A1 (0.43) | SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654973-A1 | HEPATITIS B COMBINATION THERAPIES | Aligos Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| WO-2024158904-A1 | HEPATITIS B COMBINATION THERAPIES | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | claimed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4654973-A1 | HEPATITIS B COMBINATION THERAPIES | Aligos Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250345390-A1 | COMBINATION THERAPIES | GILEAD SCIENCES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250345389-A1 | COMBINATION THERAPIES | GILEAD SCIENCES INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4626879-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250237642-A1 | PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF | UNIV EMORY (US) | 2025-07-24 | — | — | US | disclosed |
| CN-119591606-A | Pyrrolo-ring compounds, and preparation method and application thereof | 成都微芯药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025015063-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2023172635-A1 | PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF | EMORY UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116504302-A | Novel hepatitis B virus capsid assembly regulator de novo design and virtual screening method based on generation model and computational chemistry | 南京大学 | 2023-07-28 | — | — | CN | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023114365-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230127898-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-06 | — | — | US | disclosed |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2022266236-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-109153640-B | Eliminating hepatitis B virus with antiviral agent | 埃默里大学 | 2022-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | SLC10A1 225/4885TSHR 4281/4885MAPT 1087/4885 |
| US-20250345390-A1 | COMBINATION THERAPIES | HDGF, GLP1R, VIP | SLC10A1 8/4885TSHR 589/4885MAPT 3938/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | SLC10A1 7/4885TSHR 2323/4885MAPT 2382/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | SLC10A1 61/4885TSHR 133/4885MAPT 4312/4885 |
| US-20230127898-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, COPB2 | SLC10A1 79/4885TSHR 4400/4885MAPT 1310/4885 |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | SLC10A1 7/4885TSHR 2323/4885MAPT 2382/4885 |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | SLC10A1 7/4885TSHR 2323/4885MAPT 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.